Cancer Capital Corp financial data

Symbol
CNCL on OTC
Industry
Blank Checks
Location
440 East 400 South, Ste 300, Salt Lake City, UT
State of incorporation
WY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 21, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.02 % -49.5%
Debt-to-equity -100 % +3.6%
Return On Equity 9.26 % -2.32%
Return On Assets -456 % -101%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.15M shares
Common Stock, Shares, Outstanding 6.15M shares
Entity Public Float 0 USD
Common Stock, Value, Issued 6.15K USD 0%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 19.9K USD +12.1%
Operating Income (Loss) -19.9K USD -12.1%
Net Income (Loss) Attributable to Parent -43.4K USD -7.28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.11K USD -72.7%
Assets, Current 4.11K USD -72.7%
Assets 4.11K USD -72.7%
Liabilities, Current 488K USD +7.12%
Liabilities 488K USD +7.12%
Retained Earnings (Accumulated Deficit) -537K USD -8.79%
Stockholders' Equity Attributable to Parent -484K USD -9.85%
Liabilities and Equity 4.11K USD -72.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.5K USD +16.6%
Common Stock, Shares Authorized 20M shares
Common Stock, Shares, Issued 6.15M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.5K USD +16.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.11K USD -72.7%
Deferred Tax Assets, Valuation Allowance 106K USD +8.13%
Deferred Tax Assets, Operating Loss Carryforwards 106K USD +8.13%
Additional Paid in Capital 47.1K USD 0%
Interest Expense 10.4K USD +0.71%